The World Health Organization has issued its first global guidelines on treating obesity in children and adolescents, and the message to parents, doctors and drug makers is plain: food, movement and family support come first, and medicines and surgery are for older adolescents who have not responded to supervised care. The guidelines were released on October 7, 2026.

“The foundation of obesity care for children and adolescents is not medicine or surgery,” said Dr Luz María De Regil, Director of WHO’s Department of Nutrition and Food Safety. “Our priority must be to ensure that every child and adolescent can access quality care.”

The scale of the problem

WHO says 170 million children and adolescents aged 5 to 19 were living with obesity in 2024: about 70 million aged 5 to 9 and 100 million aged 10 to 19. Prevalence in this age group has quadrupled since 1990, rising from 2 per cent to 8 per cent. WHO describes obesity as a chronic, relapsing disease that can raise the risk of type 2 diabetes and cardiovascular disease early in life, and notes that affected children can face stigma, discrimination and bullying. According to Reuters, UNICEF data show obesity has surpassed underweight as the most common form of malnutrition among school-age children and adolescents worldwide.

What the guidelines say

• Lifestyle care for all: WHO strongly recommends structured dietary, physical activity and behaviour-change programmes for children and adolescents with obesity, delivered individually or as multimodal programmes, with parents or caregivers involved.
• Under 10: WHO does not recommend medication, bariatric surgery or weight-loss devices for children aged 0 to 9.
• Ages 10 to 19, medicines: Approved medicines may be considered only if a supervised multimodal lifestyle programme has not achieved the desired results.
• Adolescents with severe obesity: Bariatric surgery may be considered under strict conditions. According to Reuters, this applies to physically and mentally mature adolescents after six months of unsuccessful treatment. Health Policy Watch reports that the eligibility threshold is a BMI-for-age more than four standard deviations above the WHO growth reference median. WHO scientist Dr Maria Nieves Garcia Casal described the surgery recommendation as conditional because the balance of benefits and harms “are not entirely clear.”
• Digital tools: Conditionally recommended, with caregiver supervision.
• Mental health: Obesity and mental health conditions should be addressed early and together.
• Goals: Care should be long-term and person-centred, aiming at health, functioning and well-being, not weight loss alone.

The GLP-1 question

WHO’s page refers only to “approved medicines” and names no drug, and according to Health Policy Watch the guidelines do not recommend a specific weight-loss drug, as the long-term effects in children are not well understood. Reuters says Novo Nordisk’s Wegovy and Saxenda can be used by some adolescents aged 12 and older in the US and EU, with Saxenda also allowed in the EU for some children aged 6 to 11. WHO says it had little research on safety or efficacy under 10, and De Regil said the field is evolving and the evidence may be updated as trial data emerge. In December 2025, WHO added GLP-1 medicines as one possible treatment for adults.

Health Policy Watch cites a Pediatrics study finding that GLP-1 prescriptions for children aged 8 to 11 rose sharply between 2019 and 2026, and a Lurie Children’s Hospital analysis linking the drugs to possible nutritional deficiencies, most notably vitamin D, while only 5 per cent of paediatric patients on them received nutritional counselling. “As appropriate pediatric use of GLP-1s becomes more widespread, we need to understand the risks,” said Dr Justin Ryder, senior author of the Lurie study.

What it means

For doctors, the guidelines set a global baseline that puts supervised, family-based lifestyle programmes ahead of drugs, which may restrain the use of GLP-1 medicines in younger children. For parents, they signal that obesity in a child is a medical condition to be managed with long-term support, and not a failure of willpower, a framing WHO backs with its emphasis on stigma and mental health. For governments, WHO says treatment alone cannot stop the rise and calls for regulatory and fiscal measures to make healthy diets and physical activity affordable, plus action across education, urban planning, transport and social protection. Health Policy Watch notes that childhood obesity has plateaued in many high-income countries but is rising in low- and middle-income countries.

India is among the countries to watch. The World Obesity Atlas 2026, as summarised by Drishti IAS citing The Hindu, puts the country at about 41 million children with high BMI, the second-highest number after China, including about 14 million classified as obese. These are overweight-and-obesity figures from a different source and are not comparable with WHO’s 170 million obesity-only global count. WHO’s page does not mention India.

What the guidelines do not settle

WHO’s release does not state the number of recommendations, certainty ratings or the guideline group. Health Policy Watch reports the recommendations rest on a review of 35 scholarly review articles. Cost and access to treatment are not addressed in the reports reviewed here, and no outside critics are quoted.